Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
25.81
+0.79 (+3.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ultragenyx Pharmaceutical Inc. - Common Stock
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session
↗
July 19, 2022
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue...
Via
Benzinga
Why U.S. Stocks Are Trading Higher; Housing Starts Drop Further In June
↗
July 19, 2022
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 350 points on Tuesday.
Via
Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
↗
July 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Ultragenyx's Neurogenetic Disorder Candidate Shows Favorable Tolerability, Clinical Activity
↗
July 19, 2022
Via
Benzinga
Ultragenyx Sells One-Third Of Future North American Crysvita Royalties For $500M
↗
July 14, 2022
Via
Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
↗
July 18, 2022
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...
Via
Benzinga
What 6 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
↗
July 01, 2022
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter:
Via
Benzinga
Netflix To $210? Here's The Biggest Price Target Changes For Friday
↗
July 01, 2022
Piper Sandler cut The Goldman Sachs Group, Inc. (NYSE: GS) price target from $430 to $410. Goldman Sachs shares fell 0.1% to $296.79 in pre-market trading.
Via
Benzinga
Expert Ratings for Ultragenyx Pharmaceutical
↗
May 24, 2022
Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Regeneron's Evkeeza Reduces Bad Cholesterol By 48% In Children Aged 5-11 Years
↗
May 23, 2022
Via
Benzinga
Earnings Scheduled For February 10, 2022
↗
February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.
Via
Benzinga
Earnings Scheduled For November 2, 2021
↗
November 02, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...
Via
Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
↗
May 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
↗
May 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
↗
May 16, 2022
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from...
Via
Benzinga
Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know
↗
May 10, 2022
Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00. Shares of Ultragenyx Pharmaceutical are trading up 2.9%...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
↗
May 06, 2022
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter:
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
↗
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Ultragenyx Pharmaceutical's Earnings Outlook
↗
May 04, 2022
Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
↗
March 16, 2022
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
↗
March 16, 2022
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to...
Via
Benzinga
Where Ultragenyx Pharmaceutical Stands With Analysts
↗
March 16, 2022
Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Ultragenyx Pharmaceutical: Q4 Earnings Insights
↗
February 10, 2022
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
↗
February 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Ultragenyx Pharmaceutical inc (RARE) Q3 2021 Earnings Call Transcript
↗
November 03, 2021
RARE earnings call for the period ending October 2, 2021.
Via
The Motley Fool
Topics
Earnings
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
↗
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
↗
February 06, 2022
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
↗
September 30, 2021
Over the past 3 months, 4 analysts have published their opinion on Ultragenyx Pharmaceutical (NASDAQ:
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
January 19, 2022
During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
↗
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
